Media headlines about United Therapeutics (NASDAQ:UTHR) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. United Therapeutics earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.7316468937748 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities analysts have recently issued reports on the company. Wedbush restated an “outperform” rating and set a $232.00 price objective (up from $213.00) on shares of United Therapeutics in a research report on Wednesday, December 27th. ValuEngine upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 26th. Oppenheimer raised their price objective on United Therapeutics to $180.00 and gave the stock an “outperform” rating in a research report on Friday, January 5th. TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Finally, BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $138.50.
Shares of United Therapeutics (UTHR) opened at $142.93 on Friday. The firm has a market capitalization of $6,160.00, a P/E ratio of 12.60 and a beta of 1.41. United Therapeutics has a 1-year low of $112.01 and a 1-year high of $169.89.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics had a return on equity of 57.06% and a net margin of 62.02%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $4.23 earnings per share. equities analysts expect that United Therapeutics will post 12.96 EPS for the current fiscal year.
In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,265 shares of the firm’s stock in a transaction that occurred on Thursday, October 19th. The stock was sold at an average price of $119.38, for a total value of $151,015.70. Following the completion of the sale, the chief executive officer now owns 1,405 shares of the company’s stock, valued at $167,728.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $122.00, for a total value of $70,760.00. Following the completion of the sale, the director now directly owns 2,135 shares of the company’s stock, valued at approximately $260,470. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,773 shares of company stock valued at $1,925,637. 7.80% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/12/united-therapeutics-uthr-getting-somewhat-positive-press-coverage-report-shows.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.